-
Calcium supplementation in women; type 2 diabetes treatments and pancreatitis risk; treating chronic idiopathic urticaria; rivaroxaban and VTE; and FDA actions.
-
A trial fibrillation (AF) is a major source of morbidity in patients and cost to the health care community. In the presence of risk factors for thromboembolism, AF is associated with an increased risk of stroke, and this risk is reduced with warfarin.
-
-
The use of thrombolysis for prosthetic valve thrombosis (PVT) is controversial and various guidelines rate it differently. However, since PVT carries a significant mortality risk, more information on proposed therapies would be valuable.
-
The REduction of Atherothrombosis for Continued Health (REACH) study is an international registry of patients on antithrombic therapy that provides an opportunity to evaluate the risk of ischemic and bleeding outcomes in patients with coronary artery disease (CAD).
-
-
A new product has been approved for the urgent reversal of warfarin or other vitamin K antagonists anticoagulation in the setting of acute bleeding. This human plasma-derived product contains vitamin K-dependent coagulation Factors II, VII, IX, and X as well as antithrombotic Protein C and Protein S. It is heat-treated and viral filtered. Prothrombin complex concentrate (PCC) is manufactured by CSL Behring GmbH in Germany and marketed by CSL Behring LLC as Kcentra. The product has been licensed in Germany since 1996.
-
Optimism is associated with a significantly healthier lipid profile than is present in less optimistic persons, possibly due to healthier behaviors and lower body mass indices, which are found with increased frequency in optimistic individuals.
-
Among deployed U.S. service members who died of combat or unintentional injuries and received autopsies, the prevalence of atherosclerosis varied by age and cardiovascular risk factors.
-